• Home
  • NEW DAY MEDICINE
  • 9 (59) 2023
  • 74 -9 (59) 2023 - Tаjiуeva N.U., Rabbimova N.T. - CLINICAL AND LABORATORY CHARACTERISTICS OF PURULENT MENINGITIS/MENINGOENCEPHALITIS CAUSED BY S. PNEUMONIAE IN ADULTS

74 -9 (59) 2023 - Tаjiуeva N.U., Rabbimova N.T. - CLINICAL AND LABORATORY CHARACTERISTICS OF PURULENT MENINGITIS/MENINGOENCEPHALITIS CAUSED BY S. PNEUMONIAE IN ADULTS

CLINICAL AND LABORATORY CHARACTERISTICS OF PURULENT MENINGITIS/MENINGOENCEPHALITIS CAUSED BY S. PNEUMONIAE IN ADULTS

Tаjiуeva N.U. - Tashkent Medical Academy

Rabbimova N.T. - Samarkand State Medical University

Matyakubova F.E. - Tashkent Medical Academy

Resume

Pneumococcal meningitis is characterized by a severe course, and the mortality rate can reach up to 15-20%, while with meningococcal meningitis the mortality rate is 5-7 times less, and with purulent meningitis caused by Haemophilus influenzae type b bacterium it is 2-4 times less. Pneumococcal meningitis/meningoencephalitis in the examined patients was characterized by a severe complicated course, occurring with damage to the central nervous system and long-term residual manifestations, affecting the quality of life of patients after the disease.

Key words: pneumococcal infection, meningitis, S.pneumoniae, procalcitonin

First page

409

Last page

415

For citation: Tаjiуeva N.U., Rabbimova N.T., Matyakubova F.E. – CLINICAL AND LABORATORY CHARACTERISTICS OF PURULENT MENINGITIS/MENINGOENCEPHALITIS CAUSED BY S. PNEUMONIAE IN ADULTS//New Day in Medicine 2023 9(59): 409-415 https://newdaymedicine.com/index.php/2023/10/18/l-465/

LIST OF REFERENCES:

  1. Даминов Т.А. и др. Клиническая характеристика инвазивных пневмококковых заболеваний у детей в Узбекистане // Детские инфекции. 2015;14(2):11-16.
  2. Вакцинопрофилактика пневмококковой инфекции. Федеральные клинические рекомендации [электронный ресурс] / Союз Педиатров России; НП «НАСКИ». – М., 2015. – 24 с. Режим доступа: http://nasci.ru/_resources/directory/201/common/2015_4_Pnevmo_vak_new.p
  3. WHO. Estimates of disease burden and cost-effectiveness [electronic resourse] / WHO. – Geneva, 2017. – Mode of access: https://www.who.int/immunization/monitoring_surveillance/burden/estimates/en/
  4. Vadlamudi N. K. et al. Incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate pneumococcal vaccine in British Columbia: A retrospective cohort study //PloS one. 2020;15(9):e0239848.
  5. Wu C. J. et al. Serotype distribution and antimicrobial susceptibility of streptococcus pneumoniae in pre- and post-PCV7/13 Eras, Taiwan, 2002–2018 // Frontiers in microbiology. 2020;11:557404.

    file

    download